Propanc Biopharma, Inc. (PPCB)

Propanc Biopharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Selling, General & Admin	53.67	1.29	1.53	1.73	1.58	3.31
Research & Development	0.22	0.25	0.25	0.26	0.23	0.18
Operating Expenses	53.89	1.54	1.78	1.99	1.81	3.49
Operating Income	-53.89	-1.54	-1.78	-1.99	-1.81	-3.49
Interest Expense	-0.4	-0.67	-0.53	-0.57	-0.45	-1.75
Interest & Investment Income	0	0	0	0.01	0	0
Currency Exchange Gain (Loss)	-0.05	0.02	0.01	-0.04	0.03	-0.14
Other Non Operating Income (Expenses)	-0.05	0.18	-0.53	-0.1	-0.01	0.44
EBT Excluding Unusual Items	-54.4	-2	-2.83	-2.7	-2.24	-4.94
Other Unusual Items	-0.81	0.05	0.04	-0.02	0.1	0.07
Pretax Income	-55.21	-1.95	-2.79	-2.71	-2.14	-4.88
Income Tax Expense	-0	-0.13	-0.13	-0.05	-0.11	-0.13
Net Income	-55.21	-1.82	-2.66	-2.66	-2.03	-4.74
Preferred Dividends & Other Adjustments	-	0.19	0.47	0.7	0.39	-
Net Income to Common	-55.21	-2.01	-3.13	-3.36	-2.42	-4.74
Free Cash Flow	-0.64	-0.94	-1.11	-1.44	-1.15	-1.85
EBITDA	-53.89	-1.54	-1.77	-1.99	-1.81	-3.49
D&A For EBITDA	0	0	0	0	0	0
EBIT	-53.89	-1.54	-1.78	-1.99	-1.81	-3.49

Source: S&P Global Market Intelligence. Standard template. Financial Sources.